Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- ARB + CCB Combination Drugs Ranked in Top Positions in HP, GP Markets: RepTrack Survey
February 28, 2011
- WT1 mRNA Assay Kit Otsuka Approved for MDS
February 28, 2011
- New Drugs Improve Range of Options for Osteoporosis: 2
February 28, 2011
- Eisai Ties Up with Teikoku Seiyaku for Transdermal Aricept Formulation in Japan
February 21, 2011
- Importance of Close Links between Clinical Trials, Studies Highlighted at Gene Therapy Symposium
February 21, 2011
- Medipal Aims at Sales of ¥3 Tril. in FY2013
February 21, 2011
- Look at New Trends in Emerging Countries: Mr Hasegawa
February 21, 2011
- Price Settlement Rate Down to Levels before Emergency Call
February 21, 2011
- Takeda Begins PIII Trial of Alogliptin in China
February 21, 2011
- New Drugs Improve Range of Options for Osteoporosis: 1
February 21, 2011
- Korosho to Carry Out Case Studies to Promote Use of Generics
February 21, 2011
- Janssen Launches Once-Daily Fentanyl Patch
February 21, 2011
- No Differences in Impurity Contents in 6 Cisplatin Products: NIHS Study Group
February 21, 2011
- Astellas Licenses Fidaxomicin from Optimer
February 21, 2011
- Sawai: First 3-Qtr Sales, Profits Show Double-Digit Growth
February 21, 2011
- Astellas Creates Sales Subsidiary in Australia
February 21, 2011
- PHARMA JAPAN Lexicon: 47
February 21, 2011
- Santen Allies with DBJ
February 21, 2011
- Korosho to Review Current Risk Classification of OTC Drugs
February 21, 2011
- Otsuka Holds Sufficient Stock of IFN from Hayashibara
February 21, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…